|
|
|
|
|
|||||||
|
Session 76
Poster Session
HIV Resistance and Fitness 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 572-T. | High Prevalence of Insertions in HIV p6 PTAP Region in Drug Naïve Individuals Starting Antiretroviral Therapy: Potential Clinical Implications W. Dong, Z. Brumme, K. Chan, R. Hogg, M. V. O'Shaughnessy, J. S. G. Montaner, and P. R. Harrigan* British Columbia Ctr. for Excellence in HIV/AIDS, Vancouver, Canada
| ||
| 573-T. | Novel Mutations in HIV-1 Integrase Associated with Resistance to Diketo Acids M. Witvrouw*1, V. Fikkert1, B. Van Maele1, C. Pannecouque1, N. Neamati2, T. R. Burke Jr.3, G. Pais3, E. De Clercq1, and Z. Debyser1 1Rega Inst. for Med. Res., Katholieke Univ., Leuven, Belgium; 2Univ. of Southern California, Los Angeles; and 3NCI, NIH, Bethesda, MD
| ||
| 574-T. | Fine Structure Analysis of HIV Sequence Variation in Vivo: Longitudinal Study of Drug Naïve Patients and Dynamics of Response to Initiating HAART F. Maldarelli*1, M. Kearney1, S. Palmer1, D. Rock2, J. Falloon2, J. Mican2, S. Liu2, A. Pau3, M. VanHoutte4, L. Michels4, K. Hurtogs4, R. Stephens5, J. Mellors6, and J. Coffin1 1NCI, NIH, Frederick, MD; 2NIAID, NIH, Bethesda, MD; 3NIH, Bethesda, MD; 4Virco, Mechelen, Belgium; 5SAIC, Frederick, MD; and 6Univ. of Pittsburgh, PA
| ||
| 575-T. | Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Virologic Failure of Combination Antiretroviral Therapy J. D. Barbour1, 3, T. Wrin2, R. M. Grant1, 3, M. R. Segal1, C. J. Petropoulos2, and S. G. Deeks*1 1Univ. of California, San Francisco; 2ViroLogic, Inc., South San Francisco; and 3Gladstone Inst. of Immunology and Virology, San Francisco, CA
| ||
| 576-T. | A Pilot Study to Analyze HIV-1 Fitness Evolution under a Protease InhibitorBased Therapy Shows a Diverse Response Depending of the Basal Genotypic Context of the Virus J. Weber*1, H. Valdez2, H. R. Rangel1, B. Chakraborty1, E. Connick3, K. Smith4, A. Landay4, D. Kuritzkes3, M. Lederman1, and M. Quinones-Mateu1 1Cleveland Clin. Fndn., OH; 2Case Western Reserve Univ., Cleveland, OH; 3Univ. of Colorado Hlth. Sci. Ctr., Denver; and 4Rush Presbyterian St. Luke's Med. Ctr., Chicago, IL
| ||
| 577-T. | Impaired in Vitro Fitness of Nevirapine Resistant HIV-1 Mutants K. Soderberg*, M. Thompson, and L. Alexander Yale Univ. Sch. of Med., New Haven, CT
| ||
| 578-T. | Pausing during Initiation of HIV-1 Reverse Transcription Represents an Important Determinant for Viral Replication Fitness X. Wei*, C. Liang, M. Gštte, and M. A. Wainberg Lady Davis Inst., Jewish Gen. Hosp., Montreal, QC, Canada
| ||
| 579-T. | T69D/N pol Mutation, HIV-1 RNA Levels and Syncytium-Inducing (SI) Phenotype were Associated with CD4 Cell Depletion during Didanosine Therapy W. E. Naugler*1, F. H. Yong2, V. J. Carey2, J. Dragavon1, R. W. Coombs1, and L. M. Frenkel1 1Univ. of Washington, Seattle and 2Harvard Univ., Boston, MA
|
